文献速递MDS 与骨髓增殖性肿瘤

骨髓增生异常综合征分子国际预后评分系统的真实世界验证

Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes.
PubMed 文献 · J Clin Oncol · 2023-03-17

该研究回顾性分析了GenoMed4All联盟2876例原发性骨髓增生异常综合征(MDS)患者,验证分子国际预后评分系统(IPSS-M)的预后价值。IPSS-M在总生存和无白血病生存的区分度上均优于修订版国际预后评分系统(IPSS-R),并显著改善造血干细胞移植(HSCT)后复发和生存的预测。在高危接受去甲基化药物(HMA)治疗的患者中,IPSS-M未能分层个体缓解概率。

要点

  • IPSS-M在全部临床终点上较IPSS-R改善预后区分度,总生存一致性0.81 vs 0.74。
  • 46%患者IPSS-M风险分组较IPSS-R发生改变,其中23.6%升级、22.4%降级。
  • HSCT患者中IPSS-M显著改善复发和移植后生存预测,总生存一致性0.76 vs 0.60。

核心结论

  • IPSS-M改善MDS预后判断,可能有助于更有效地选择HSCT候选者。
  • 除基因突变外,其他因素可能参与决定HMA敏感性。
  • 定义最少相关基因集可能促进该评分的临床实施。

研究设计与样本

  • 回顾性分析GenoMed4All联盟2876例原发性MDS患者。

主要发现

  • IPSS-M较IPSS-R改善所有临床终点的预后区分度:总生存一致性0.81 vs 0.74,无白血病生存一致性0.89 vs 0.76。
  • 即使无可检测基因突变的患者,IPSS-M仍改善预后区分度。
  • 46%患者IPSS-M风险分组较IPSS-R改变:23.6%升级,22.4%降级。
  • HSCT患者中IPSS-M较IPSS-R显著改善疾病复发风险和移植后生存概率预测:总生存一致性0.76 vs 0.60,复发概率一致性0.89 vs 0.70。
  • 高危接受HMA治疗患者中,IPSS-M未能分层个体缓解概率;缓解持续时间和生存概率与IPSS-M风险呈负相关。

关键数值与推荐

  • 总生存一致性:IPSS-M 0.81 vs IPSS-R 0.74。
  • 无白血病生存一致性:IPSS-M 0.89 vs IPSS-R 0.76。
  • HSCT患者总生存一致性:IPSS-M 0.76 vs IPSS-R 0.60;复发概率一致性:IPSS-M 0.89 vs IPSS-R 0.70。
  • IPSS-M风险分组改变比例46%,其中升级23.6%、降级22.4%。
  • 定义与评分高性能相关的15个相关基因的最少集合。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Myelodysplastic syndromes (MDS) are heterogeneous myeloid neoplasms in which a risk-adapted treatment strategy is needed. Recently, a new clinical-molecular prognostic model, the Molecular International Prognostic Scoring System (IPSS-M) was proposed to improve the prediction of clinical outcome of the currently available tool (Revised International Prognostic Scoring System [IPSS-R]). We aimed to provide an extensive validation of IPSS-M. METHODS: A total of 2,876 patients with primary MDS from the GenoMed4All consortium were retrospectively analyzed. RESULTS: IPSS-M improved prognostic discrimination across all clinical end points with respect to IPSS-R (concordance was 0.81 v 0.74 for overall survival and 0.89 v 0.76 for leukemia-free survival, respectively). This was true even in those patients without detectable gene mutations. Compared with the IPSS-R based stratification, the IPSS-M risk group changed in 46% of patients (23.6% and 22.4% of subjects were upstaged and downstaged, respectively).In patients treated with hematopoietic stem cell transplantation (HSCT), IPSS-M significantly improved the prediction of the risk of disease relapse and the probability of post-transplantation survival versus IPSS-R (concordance was 0.76 v 0.60 for overall survival and 0.89 v 0.70 for probability of relapse, respectively). In high-risk patients treated with hypomethylating agents (HMA), IPSS-M failed to stratify individual probability of response; response duration and probability of survival were inversely related to IPSS-M risk.Finally, we tested the accuracy in predicting IPSS-M when molecular information was missed and we defined a minimum set of 15 relevant genes associated with high performance of the score. CONCLUSION: IPSS-M improves MDS prognostication and might result in a more effective selection of candidates to HSCT. Additional factors other than gene mutations can be involved in determining HMA sensitivity. The definition of a minimum set of relevant genes may facilitate the clinical implementation of the score.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Sauta E, Robin M, Bersanelli M, et al. Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. J Clin Oncol. 2023. PMID: 36930857. doi:10.1200/JCO.22.01784

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。